Cambium Bio (ASX:CMB) Days Sales Outstanding : 0.00 (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Cambium Bio Days Sales Outstanding?

Cambium Bio's average Accounts Receivable for the six months ended in Dec. 2023 was A$0.00 Mil. Cambium Bio's Revenue for the six months ended in Dec. 2023 was A$0.00 Mil.

The historical rank and industry rank for Cambium Bio's Days Sales Outstanding or its related term are showing as below:

During the past 10 years, Cambium Bio's highest Days Sales Outstanding was 321.76. The lowest was 0.42. And the median was 20.16.

ASX:CMB's Days Sales Outstanding is not ranked ^*
in the Biotechnology industry.
Industry Median: 72.67
* Ranked among companies with meaningful Days Sales Outstanding only.

Cambium Bio's Days Sales Outstanding stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00).

Cambium Bio Days Sales Outstanding Historical Data

The historical data trend for Cambium Bio's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cambium Bio Days Sales Outstanding Chart

Cambium Bio Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Days Sales Outstanding

Get a 7-Day Free Trial

321.76

67.26

Cambium Bio Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Cambium Bio's Days Sales Outstanding

For the Biotechnology subindustry, Cambium Bio's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cambium Bio's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cambium Bio's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Cambium Bio's Days Sales Outstanding falls into.

Cambium Bio Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Cambium Bio's Days Sales Outstanding for the fiscal year that ended in Jun. 2023 is calculated as

	Days Sales Outstanding (A: Jun. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Jun. 2022 )	+	Accounts Receivable (A: Jun. 2023 ))	/	count )	/	Revenue (A: Jun. 2023 )	*	Days in Period
=	( (0.111	+	0)	/	1 )	/	0	*	365
=	0.111					/	0	*	365
=	N/A

Cambium Bio's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Jun. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365 / 2
=	0					/	0	*	365 / 2
=	N/A

Cambium Bio (ASX:CMB) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Cambium Bio Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Cambium Bio's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Cambium Bio (ASX:CMB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cambium Bio Ltd (ASX:CMB) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

16 Goodhope Street, Paddington, Sydney, NSW, AUS, 2021

Website

https://www.regeneus.com.au

Regeneus Ltd is a clinical-stage regenerative medicine company in Australia. It mainly develops a portfolio of cell-based therapies to address unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology diseases. The company uses stem cell and immuno-oncology technologies to develop cell-based therapies. Its product pipeline consists of two platform technologies, Progenza and Sygenus, across three target therapeutic areas namely osteoarthritis, neuropathic pain, and skin wound healing. The company has one operating segment being the development of innovative cell-based therapies to address significant unmet medical needs in human and veterinary health.

Cambium Bio (ASX:CMB) Headlines

No Headlines